

Gender: Male | Birth year: 1965 | WHO: 1

Tumor: Lung - Squamous cell carcinoma | Lesions: Liver, Lung | Stage: III

Summary

Clinical summary

Relevant systemic treatment history	6/2023-6/2024	Carboplatin+Pemetrexed continued with Pemetrexed maintenance
	7/2024-8/2024	Docetaxel
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	1/2020	Acute myocardial infarction
	1/2000	Bipolar disorder

Recent molecular results

NGS Lung Panel 1.2 (15-Sep-2024)

Biopsy location	Lung
Molecular tissue of origin prediction	Unknown
Tumor mutational load / burden	Unknown / TMB low (8)
Microsatellite (in)stability	Stable
HR status	Proficient
High driver mutations	PIK3CA E545K
Amplified genes	None
Deleted genes	TP53, KEAP1
Homozygously disrupted genes	None
Gene fusions	None
Virus detection	None
Potentially actionable events with medium/low driver:	None
IHC results	PD-L1: Score < 1%

Example trials that are open and potentially eligible (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 05 PICKME3CA	Dose expansion - monotherapy - NSCLC	PIK3CA E545K	None

Example trials that are open and potentially eligible but currently have no slots available (1 cohort from 1 trial)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose escalation - monotherapy		None

Trial Matching Summary

Example trials and cohorts that may be eligible, but are closed (1)

Trial	Cohort	Molecular	Warnings
METC 01 IEMOEN	Dose expansion - monotherapy		None

Example trials and cohorts that are considered ineligible (5)

Trial	Cohort	Molecular	Ineligibility reasons
METC 05 PICKME3CA	Dose expansion - monotherapy - Other cancer types	PIK3CA E545K	Has tumor belonging to lung non-small cell carcinoma
METC 02 KAYRAS	Applies to all cohorts below Dose expansion - monotherapy - Colorectum Dose expansion - monotherapy - NSCLC	None	G12D not detected in KRAS No colorectal cancer
METC 03 NO-SEE797ES	Dose escalation - monotherapy		No variants in codon(s) C797 in EGFR
METC 04 TEDR1	Lung cancer C797S cohort		C797S not detected in EGFR

Open cohorts with no slots available are shown in grey.

Trial Matching Details

Potentially eligible open trials & cohorts

METC 01

Potentially eligible	Yes
Acronym	IEMOEN
Title	Phase I first-in-human study to evaluate safety of IEMOEN, a new PD-L1 inhibitor in advanced solid tumors

Rule	Reference	Evaluation
E-02	Has hemoglobin below 6 mmol/l	<b>WARN</b>  Hemoglobin 8.2 mmol/L exceeds minimum of 6.0 mmol/L, but measurement occurred before 03-Aug-2024
E-03	Has absolute neutrophil count below 1.5 x 10^9/l	<b>UNDETERMINED</b>  No measurement found for absolute neutrophil count
I-01	Patients must be ≥18 years old.	<b>PASS</b>  Patient is at least 18 years old
I-02	IEMOEN monotherapy is indicated for the treatment of adults with advanced/metastatic solid tumors.	<b>PASS</b>  Patient has solid primary tumor Tumor stage III is considered locally advanced Tumor stage III is considered metastatic
I-03	Patient should have exhausted applicable available standard-of-care treatments.	<b>PASS</b>  SOC considered exhausted since platinum doublet in treatment history
E-01	Has an active autoimmune disease that requires systemic treatment and poses a risk according to the investigator.	<b>PASS</b>  Patient has no other condition belonging to category autoimmune disease

METC 01 - Dose escalation - monotherapy

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	No

METC 01 - Dose expansion - monotherapy

Cohort ID	B
Potentially eligible?	Yes
Open for inclusion?	No
Has slots available?	No

METC 05

Potentially eligible	Yes
Acronym	PICKME3CA
Title	A phase 1/2 trial of ABC123 +/- platinum doublet in PIK3CA-mutated solid cancer

Rule	Reference	Evaluation
I-03	ALAT and ASAT should be at most 3*ULN, or at most 5*ULN in case of liver metastases.	UNDETERMINED  ASAT and ALAT are not present or cannot be evaluated
I-01	Patient is ≥18 years old.	PASS  Patient is at least 18 years old
I-02	Has locally advanced or metastatic cancer.	PASS  Tumor stage III is considered locally advanced  Tumor stage III is considered metastatic
I-04	Patient has confirmed activating PIK3CA mutation	PASS  Activating mutation(s) detected in gene + PIK3CA: PIK3CA E545K

METC 05 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	Yes
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-03	Has non small cell lung cancer.	PASS  Patient has tumor belonging to doid term(s) lung non-small cell carcinoma

METC 05 - Dose expansion - monotherapy - Other cancer types

Cohort ID	B
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-03	Has solid cancer, other than non small cell lung cancer.	FAIL  Patient has tumor belonging to doid term(s) lung non-small cell carcinoma

Other trials & cohorts

METC 02

Potentially eligible	No	
Acronym	KAYRAS	
Title	A phase 1/2 trial for first in-human usage of KAYRAS, a new specific KRAS G12D inhibitor in NSCLC and colorectal cancer	
Rule	Reference	Evaluation
I-04	Patient has confirmed KRAS G12D mutation	FAIL  None of G12D detected in gene KRAS

METC 02 - Dose expansion - monotherapy - NSCLC

Cohort ID	A
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

METC 02 - Dose expansion - monotherapy - Colorectum

Cohort ID	B
Potentially eligible?	No
Open for inclusion?	Yes
Has slots available?	Yes

Rule	Reference	Evaluation
I-02	KAYRAS monotherapy is indicated for the treatment of NSCLC or colorectal patients with metastatic cancer.	FAIL  Patient has no colorectal cancer

METC 02 - Dose expansion - monotherapy - Colorectum

Acronym	NO-SEE797ES	
Title	Phase I trial for development of NO-SEE797ES, a specific inhibitor for EGFR with C797 mutations but not C797S in solid tumors	
Rule	Reference	Evaluation
I-03	Tumors should contain EGFR C797 but not EGFR C797S mutation.	FAIL  No variants in codon(s) C797 detected in gene EGFR

METC 03

Cohort ID	<b>A</b>
Potentially eligible?	<b>No</b>
Open for inclusion?	<b>Yes</b>
Has slots available?	<b>Yes</b>

METC 03 - Dose escalation - monotherapy

5/6

All results and data described in this report are for Research Use Only and have NOT been generated using a clinically validated and controlled procedure nor is it a validated medical device. The results should NOT be used for diagnostic or treatment purposes. No rights can be derived from the content of this report.

METC 04

Potentially eligible	No	
Acronym	TEDR1	
Title	TEDR1 Trial: A phase II trial to evaluate efficacy of specific EGFR inhibitors in lung cancer	
Rule	Reference	Evaluation
I-3	Patient has a confirmed EGFR C797S mutation	FAIL None of C797S detected in gene EGFR

METC 04 - Lung cancer C797S cohort

Cohort ID	A	
Potentially eligible?	No	
Open for inclusion?	Yes	
Has slots available?	Yes	